Thursday, September 29, 2022

561.316.3330

Biotechnology News Magazine

New Quality of Life Data for Valtoco (Diazepam Nasal Spray)CIV in the Treatment of Seizure Clusters Published in Epilepsy & Behavior

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.
  • Seventy-two of 85 adult patients with seizure clusters who were enrolled in the long-term, Phase 3, open-label clinical trial of VALTOCO® (diazepam nasal spray) reported stable or increased Quality of Life (QoL) during the study, according to recent findings published online in the leading journal, Epilepsy & Behavior.

“Caregivers and patients with seizure clusters worry about when the next seizure is going to happen,” said Adrian Rabinowicz, MD, SVP Clinical Development and Medical Affairs. “These findings indicate that if we can reduce the number of seizure clusters with acute, rapid therapies, we potentially can have an impact on both seizure worry and social functioning.”

Until now, limited research has been conducted to assess QoL as a potential secondary endpoint in patients with seizure clusters. The 12-month study of diazepam nasal spray enrolled patients 6-to-65 years with seizure clusters. Adults ≥18 years completed the Quality of Life in Epilepsy (QOLIE)-31-P at baseline (day 0) and days 30, 150, 270, and 365. Participants answered questions about their health and daily activities, and responses were assigned numeric values (1-100). Higher scores indicated better QoL.

“These findings suggest the need for further study of the impact of acute, rapid therapies on QoL in this patient population,” said Sunita Misra, MD, Senior Medical Director at Neurelis. “Patients and caregivers need to feel empowered by a treatment plan that may reduce their seizure clusters while potentially improving their overall quality of life.”

QoL measures included seizure worry, overall QoL, emotional wellbeing, energy/fatigue, cognitive functioning, medication effects, and social functioning.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine